XELOX in colorectal cancer: a convenient option for the future?
Expert Rev Gastroenterol Hepatol
; 5(1): 9-19, 2011 Feb.
Article
in En
| MEDLINE
| ID: mdl-21309667
ABSTRACT
XELOX is a 3-weekly chemotherapy combination of oral capecitabine and intravenous oxaliplatin. The central hypothesis that led to its development was that it would provide a convenient and cost-effective alternative to intravenous fluorouracil-based chemotherapy doublets, without compromising on anti-tumor efficacy. Recently its role in colorectal cancer has become more established in both the metastatic and adjuvant setting. Ongoing investigation of XELOX continues in a number of directions its combination with novel biological agents, its efficacy and safety in the elderly, and the development of biomarkers that can predict its anti-tumor effect. This article provides a comprehensive and up-to-date synopsis of all pertinent clinical studies detailing this regimen and its promise for the future.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Expert Rev Gastroenterol Hepatol
Journal subject:
GASTROENTEROLOGIA
Year:
2011
Document type:
Article
Affiliation country:
United kingdom